1. Search Result
Search Result
Results for "

RCC

" in MedChemExpress (MCE) Product Catalog:

27

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

12

Recombinant Proteins

1

Isotope-Labeled Compounds

16

Antibodies

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139782
    SKLB325
    2 Publications Verification

    Histone Demethylase Apoptosis Cancer
    SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis . SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .
    SKLB325
  • HY-18728
    STF-31
    Maximum Cited Publications
    17 Publications Verification

    GLUT Autophagy Cancer
    STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .
    STF-31
  • HY-112780
    UC2288
    5+ Cited Publications

    MDM-2/p53 Apoptosis Cancer
    UC2288 is a potent and orally active p21 attenuator (relatively selective activity for p21), which is synthesized based Sorafenib (HY-10201). UC2288 potently inhibits cancer cell growth by inducing apoptosis. UC2288 has no inhibition of VEGFR2 and Raf kinases even at 10 μM .
    UC2288
  • HY-100746
    STF-62247
    2 Publications Verification

    Autophagy Cancer
    STF-62247 is an autophagy inducer that selectively cytotoxic to VHL-deficient renal cell carcinoma (IC50 of 0.625 μM and 16 μM in RCC4 and RCC4/VHL cells, respectively) .
    STF-62247
  • HY-122615
    SPOP-IN-6b
    3 Publications Verification

    E1/E2/E3 Enzyme Cancer
    SPOP-IN-6b is a speckle-type POZ protein (SPOP) inhibitor with an IC50 of 3.58 μM (patent CN 107141287, SPOP-B-88) .
    SPOP-IN-6b
  • HY-P2324
    Gramicidin A
    1 Publications Verification

    Bacterial HIF/HIF Prolyl-Hydroxylase Antibiotic Infection Cancer
    Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A induces degradation of hypoxia inducible factor 1 α (HIF-1α) .
    Gramicidin A
  • HY-P99161

    BGB149

    TAM Receptor Cancer
    Tilvestamab (BGB149) is a humanized anti-AXL antibody that blocks AXL-mediated cell signaling. Tilvestamab significantly inhibits Gas6-induced AXL activation in 786-0-Luc RCC cells and inhibits downstream AKT phosphorylation. Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas .
    Tilvestamab
  • HY-119425

    ICRF 159

    Topoisomerase Cancer
    Razoxane (ICRF 159), a EDTA (HY-Y0682) derivative, is an orally active antiangiogenic topoisomerase II inhibitor. Razoxane has antineoplastic, antiangiogenic, and antimetastatic activities. Razoxanecan be used for the research of renal cell carcinoma (RCC), lung cancer and melanoma cancer .
    Razoxane
  • HY-I0636

    (R)-CC-10004

    Phosphodiesterase (PDE) Inflammation/Immunology
    (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast .
    (R)-Apremilast
  • HY-P99027

    LAG525; IMP701; Hu5A8

    LAG-3 Cancer
    Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
    Ieramilimab
  • HY-15960

    VDC-597 free base

    PI3K mTOR Apoptosis Cancer
    PWT-33597 (VDC-597) free base is a dual inhibitor of PI3Kα and mTOR, which can effectively block the signaling downstream of PI3K and mTOR. PWT-33597 free base is capable of inducing tumor cell apoptosis and inhibiting tumor growth. PWT-33597 free base has anti-tumor activity and can be used in the research of tumors such as renal cell carcinoma .
    PWT-33597 free base
  • HY-15960A

    VDC-597; SN33597

    PI3K mTOR Apoptosis Cancer
    PWT-33597 (VDC-597) is a dual inhibitor of PI3Kα and mTOR, which can effectively block the signaling downstream of PI3K and mTOR. PWT-33597 is capable of inducing tumor cell apoptosis and inhibiting tumor growth. PWT-33597 has anti-tumor activity and can be used in the research of tumors such as renal cell carcinoma .
    PWT-33597
  • HY-179392

    Apoptosis DNA Alkylator/Crosslinker VEGFR PDGFR Cancer
    Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Pt(IV) prodrug based on Cisplatin (HY-17394), and this design aims to enable Pt(IV) to be reduced to active Pt(II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum(IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum(IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum(IV) prodrug-1 can be used for research on renal cell carcinoma .
    Sunitinib-platinum(IV) prodrug-1
  • HY-I0636R

    (R)-CC-10004 (Standard)

    Phosphodiesterase (PDE) Reference Standards Inflammation/Immunology
    (R)-Apremilast (Standard) is the analytical standard of (R)-Apremilast. This product is intended for research and analytical applications. (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast .
    (R)-Apremilast (Standard)
  • HY-RS11784

    Small Interfering RNA (siRNA) Others

    RCC2 Human Pre-designed siRNA Set A contains three designed siRNAs for RCC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RCC2 Human Pre-designed siRNA Set A
    RCC2 Human Pre-designed siRNA Set A
  • HY-RS11783

    Small Interfering RNA (siRNA) Others

    RCC1 Human Pre-designed siRNA Set A contains three designed siRNAs for RCC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    RCC1 Human Pre-designed siRNA Set A
    RCC1 Human Pre-designed siRNA Set A
  • HY-RS21417

    Small Interfering RNA (siRNA) Others

    Rcc1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rcc1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Rcc1 Mouse Pre-designed siRNA Set A
    Rcc1 Mouse Pre-designed siRNA Set A
  • HY-119425R

    ICRF 159 (Standard)

    Topoisomerase Reference Standards Cancer
    Razoxane (Standard) is the analytical standard of Razoxane. This product is intended for research and analytical applications. Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC) .
    Razoxane (Standard)
  • HY-12085S2

    (Rac)-CC-10004 d5

    Apoptosis Phosphodiesterase (PDE) TNF Receptor Isotope-Labeled Compounds Inflammation/Immunology
    (Rac)-Apremilast-d5 is a deuterium labeled (R)-Apremilast. (R)-Apremilast ((R)-CC-10004) is a enantiomer of Apremilast .
    (Rac)-Apremilast-d5
  • HY-RS15896

    Small Interfering RNA (siRNA) Others

    XRCC1 Human Pre-designed siRNA Set A contains three designed siRNAs for XRCC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    XRCC1 Human Pre-designed siRNA Set A
    XRCC1 Human Pre-designed siRNA Set A
  • HY-RS10105

    Small Interfering RNA (siRNA) Others

    PBRM1 Human Pre-designed siRNA Set A contains three designed siRNAs for PBRM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PBRM1 Human Pre-designed siRNA Set A
    PBRM1 Human Pre-designed siRNA Set A
  • HY-P2324A

    Antibiotic Bacterial Infection
    Gramicidin A (TFA) is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A (TFA) is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A (TFA) induces degradation of hypoxia inducible factor 1 α (HIF-1α) .
    Gramicidin A TFA
  • HY-112467
    Tivozanib hydrate
    5+ Cited Publications

    AV-951 hydrate; KRN951 hydrate

    VEGFR Cancer
    Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy .
    Tivozanib hydrate
  • HY-182599

    Calcium Channel mAChR Neurological Disease
    RCC-36 hydrochloride is an L-type calcium channel inhibitor and competitive muscarinic receptor antagonist. RCC-36 hydrochloride inhibits L-type calcium currents in voltage- and concentration-dependent fashion with no effect on cardiac K + currents. RCC-36 hydrochloride suppresses maximum acetylcholine-induced contractile responses, inhibits detrusor muscle contractions induced by potassium chloride, calcium chloride, and electric field stimulation, including atropine-resistant contractions. RCC-36 hydrochloride can be used for the research of urinary frequency, urinary incontinence, and bladder overactivity .
    RCC-36 hydrochloride
  • HY-RS27936

    Small Interfering RNA (siRNA) Others
    Rcc1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Rcc1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Rcc1 Rat Pre-designed siRNA Set A
    Rcc1 Rat Pre-designed siRNA Set A
  • HY-182676

    Histone Methyltransferase Cancer
    DC541 (Compound 20) is a selective NTMT1 inhibitor with an IC50 of 0.34 μM. DC541 reduces the level of me3-RCC1 in colorectal cancer cells. DC541 is applicable to research related to colorectal cancer .
    DC541
  • HY-132304A

    PKC Inflammation/Immunology
    (1S,4R)-CC-90005 is the (1S,4R)-enantiomer of CC-90005 (HY-132304). CC-90005 is a potent, selective and orally active inhibitor of protein kinase C-θ (PKC-θ), with an IC50 of 8 nM. CC-90005 shows selectivity for PKC-θ over PKC-δ (IC50 = 4440 nM). CC-90005 can inhibit T cell activation by inhibiting IL-2 expression .
    (1S,4R)-CC-90005

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: